{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-23-000027","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.502181+00:00","generated_at":"2026-06-13T13:17:03.549930+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aurinia board explores strategic alternatives including sale; two directors resign after vote shortfall","bullets":["Board initiated exploration of strategic alternatives including sale, merger, or other transaction.","Retained JP Morgan as financial advisor; Skadden Arps and Borden Ladner Gervais as legal counsel.","Directors George Milne and Joseph Hagan resigned effective June 29 after less-than-majority support at AGM.","Korn Ferry engaged to search for two new board members.","No timetable set; no assurance of any transaction outcome."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-23-000027","json":"https://secwatch.observer/filing/0001600620-23-000027.json","markdown":"https://secwatch.observer/filing/0001600620-23-000027.md","text":"https://secwatch.observer/filing/0001600620-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000027/0001600620-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000027/auph-20230629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T13:17:03.549930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84fedb279b","claim":"George Milne resigned as director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000027/0001600620-23-000027-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"f75ecfdc9c","claim":"Joseph P. Hagan resigned as director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000027/0001600620-23-000027-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}